NGNE
What one share of Neurogene holds
Pharmaceutical Preparations
Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression.
Neurogene’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.04 |
|---|---|
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$3.98 |
| Cash and investments | $7.11 |
| Book value | $13.72 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$343.54 | $1.64 | −$253.83 | — | $422.47 |
| 2015 | — | −$216.22 | $0.26 | −$200.73 | — | $787.39 |
| 2016 | — | −$244.81 | $4.72 | −$204.69 | — | $772.01 |
| 2017 | — | −$267.50 | $2.63 | −$241.00 | — | $526.61 |
| 2018 | — | −$167.87 | $0.26 | −$168.08 | — | $385.94 |
| 2019 | — | −$321.13 | $4.06 | −$75.25 | — | $466.11 |
| 2020 | — | −$80.26 | $5.35 | −$64.63 | — | $566.45 |
| 2021 | — | −$137.83 | $7.41 | −$115.41 | — | −$270.49 |
| 2022 | — | −$130.00 | $5.05 | −$124.62 | — | — |
| 2024 | $0.05 | −$4.28 | $0.05 | −$4.07 | — | $20.89 |
| 2025 | $0.00 | −$4.24 | $0.06 | −$3.67 | — | $17.10 |